Filing Details

Accession Number:
0001567619-19-009182
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-25 16:08:11
Reporting Period:
2019-04-22
Accepted Time:
2019-04-25 16:08:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595893 Turning Point Therapeutics Inc. TPTX () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1583977 Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
1599214 Bihua Chen C/O Cormorant Asset Management, Lp
200 Clarendon Street, 52Nd Floor
Boston MA 02116
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-22 400,000 $18.00 3,099,099 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (right to buy) $2.19 2019-07-16 23,268 23,268 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2019-07-16 23,268 23,268 Indirect
Footnotes
  1. Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP ("Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, fund I, Fund II and the Account. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP, LLC ("GP I") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund, Fund I and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP I and GP II.
  2. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  3. Of the shares purchased on April 22, 2019, 367,840 were purchased for the Master Fund and 32,160 shares were purchased for the Account. As of April 22, 2019, the Master Fund held 1,351,749 shares, Fund I held 878,316 shares, Fund II held 653,145 shares, and the Account held 215,889 shares.
  4. The stock options are currently exercisable. The Master Fund and Fund I may receive up to 10,516 and 12,516 shares, respectively, upon exercise of the stock options.